Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2015

View Archived Issues

Shire reports pipeline highlights of fourth quarter 2014

Zydus completes phase I studies of ZYAN-1

Impaired mTORC1 activity linked to phenotypic changes associated with Huntington's disease

Saniona regains rights to GABA-alpha5 program

Otsuka Pharmaceutical recaps highlights of third quarter of fiscal 2014

VistaGen and NIH sign agreement for phase II AV-101 trial in major depressive disorder

FDA grants fast track designation to intranasal naloxone treatment

FDA gives orphan drug status to entrectinib for colorectal cancer

Nanjing Sanhome Pharmaceutical patents ABL inhibitors

Phase II trial of MRX-6 in pediatric atopic dermatitis does not reach primary endpoint

Alethia Biotherapeutics submits clinical trial application for AB-16B5

PBI-4050 granted U.S. orphan drug status for IPF

VBL Therapeutics reports data from VB-201 trials in psoriasis and ulcerative colitis

Roche develops neurogenesis-stimulating naphthyridines

Zenith Epigenetics reports novel bromodomain inhibitors

Nattokinase shows efficacy for ischemic brain damage

Novartis patent divulges PI3Kdelta/gamma inhibitors

Intrexon to acquire recombinant bacterial therapeutics developer ActoGeniX

Takeda Pharmaceutical patents new PDE2A inhibitors

ADAMTS13, a potential biomarker of response to thrombolysis in acute stroke

Alzheimer's Research U.K. funds three drug discovery institutes

Sprout Pharmaceuticals resubmits NDA for flibanserin in HSDD

Elite Pharmaceuticals plans phase III trial of abuse-deterrent opioid

SB-623 cell therapy shows encouraging results for chronic stroke

Pluristem Therapeutics reports results for PLX-R18 in animal model of ARS

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...